1. Home
  2. CGC vs AGEN Comparison

CGC vs AGEN Comparison

Compare CGC & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Canopy Growth Corporation

CGC

Canopy Growth Corporation

N/A

Current Price

$0.66

Market Cap

389.2M

Sector

Health Care

ML Signal

N/A

Logo Agenus Inc.

AGEN

Agenus Inc.

N/A

Current Price

$6.47

Market Cap

335.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CGC
AGEN
Founded
N/A
1994
Country
Canada
United States
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
389.2M
335.6M
IPO Year
2023
1999

Fundamental Metrics

Financial Performance
Metric
CGC
AGEN
Price
$0.66
$6.47
Analyst Decision
Buy
Strong Buy
Analyst Count
3
3
Target Price
$1.96
★ $26.33
AVG Volume (30 Days)
★ 2.2M
986.1K
Earning Date
11-06-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
84.17
★ 100.00
EPS
N/A
★ 0.96
Revenue
$12,759,000.00
★ $42,877,086.00
Revenue This Year
$21.39
$9.64
Revenue Next Year
$8.33
N/A
P/E Ratio
★ N/A
$6.75
Revenue Growth
N/A
★ 89.95
52 Week Low
$0.65
$2.71
52 Week High
$2.38
$10.19

Technical Indicators

Market Signals
Indicator
CGC
AGEN
Relative Strength Index (RSI) 21.54 39.39
Support Level N/A $6.34
Resistance Level $1.08 $8.64
Average True Range (ATR) 0.04 0.45
MACD -0.01 -0.14
Stochastic Oscillator 6.86 16.47

Price Performance

Historical Comparison
CGC
AGEN

About CGC Canopy Growth Corporation

Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: